Tim-3 expression in glioma cells is associated with drug resistance

Simple item page
dc.contributor.authorJi, Zhangen_US
dc.contributor.authorZheng, Quan Zhuen_US
dc.contributor.authorYan, Xia Lien_US
dc.contributor.authorQiu, Feng Zhuangen_US
dc.contributor.authorLai, Yuanhongen_US
dc.contributor.authorLi, Shao Fangen_US
dc.contributor.authorXu, Xiao Bingen_US
dc.contributor.authorLiu, Jian Minen_US
dc.date.accessioned2020-11-18T10:07:24Z
dc.date.available2020-11-18T10:07:24Z
dc.date.issued2019-08
dc.description.abstractObjective: T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) has been widely recognized as a negative regulator of antitumor immunity. However, the mechanism by which Tim-3 suppresses antitumor treatment in gliomas remains unclear. This study aims to explore whether Tim-3 is expressed and to evaluate its effect in drug-fasted glioma cells. Subjects and Methods: U87 and U251 glioma cell lines were tested. Cell proliferation activity, cell viability, and the protein and mRNA levels of Tim-3 were detected using CCK-8, flow cytometry, Western blotting, and reverse transcription-quantitative polymerase chain reaction, respectively. Enhancement of the sensitivity of glioma cells to chemotherapeutic agents was tested after inhibiting Tim-3 expression using Tim-3 small interfering RNAs (siRNA). Results: As temozolomide (TMZ) concentration increased, the ratio of apoptotic cells also increased accordingly. However, the level of Tim-3 expression in living cells from the high-dose group was higher than in the low- and middle-dose groups. After interfering with the expression of Tim-3 using siRNA against Tim-3, the killing effect of TMZ rose through an increase in apoptosis. Conclusions: The presence of Tim-3 mRNA and protein in glioma cells was detected. Significantly, knocking down Tim-3 expression improved the potential of TMZ treatment.en_US
dc.identifier.affiliationsDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Neurosurgery, Tumor Hospital Affiliated of Xinjiang Medical University, Xinshi District, Chinaen_US
dc.identifier.affiliationsDepartment of Rehabilitation, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Chinaen_US
dc.identifier.affiliationsDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Urology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Neurosurgery, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Chinaen_US
dc.identifier.affiliationsDepartment of Neurosurgery, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Chinaen_US
dc.identifier.citationJi Zhang, Zheng Quan Zhu, Yan Xia Li, Qiu Feng Zhuang, Lai Yuanhong, Li Shao Fang, Xu Xiao Bing, Liu Jian Min. Tim-3 expression in glioma cells is associated with drug resistance. Journal of Cancer Research and Therapeutics. 2019 Aug; 15(4): 882-888en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213448
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber4en_US
dc.relation.volume15en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_630_18en_US
dc.titleTim-3 expression in glioma cells is associated with drug resistanceen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcrt2019v15n4p882.pdf
Size:
1.63 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics